Category: Novartis

Visiongain Reports Ltd Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS…

Visiongain has published a new report entitled: Translational Regenerative Medicine Market Report 2024-2034: Forecasts by Product (Stem Cell Therapy (Autologous, Allogenic), Tissue Engineering (Scaffold, Hydrogels), Gene Therapy, Others)), by Application (Oncology, Dermatology, Musculoskeletal, Neurology, Cardiovascular, Wound Healing, Ophthalmology, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading…

The UK is home to several biotech hubs, including the famous ‘golden triangle’, made up of Oxford, Cambridge, and London. In fact, after a $700 million surge in funding in the third quarter of 2023, the UK biotech scene is now one of the most vibrant in Europe, laying the…

The company aims to use the power of AI to tackle various diseases and could receive nearly $3bn from its new research collaborations. DeepMind spin-out Isomorphic Labs has signed two deals with pharma giants to discover new drugs, which could lead to billions in profit for the company. The Alphabet…

Isomorphic Labs is a digital biology company that says its mission is to redefine drug discovery using artificial intelligence (AI) and says the collaboration with Novartis is to discover small molecule therapeutics against three undisclosed targets.   “Isomorphic Labs and Novartis hold a shared purpose to reimagine medicine to improve and…

Isomorphic Labs, a London-based spin-out of Alphabet Inc GOOG GOOGL Google’s AI R&D division DeepMind, has announced strategic partnerships with Eli Lilly And Co LLY and Novartis AG NVS.  These alliances aim to leverage AI to discover new medications to treat diseases.  The combined value of these deals is around $3 billion.  Isomorphic will receive $45 million upfront from Eli Lilly, potentially…

Key Points bluebird bio has three FDA-approved gene therapy treatments that are planning to commercialize after its $150 million secondary offering of common shares priced at $1.50 per share. bluebird bio’s latest FDA approval, LYFGENIA, is a one-time treatment for sickle cell disease, which is priced around $3.1 million per…

Job Category Any CategoryJobInternshipWork from Home Job Type Any Job TypesFull-timePart-timeContractVolunteer Location Any CountryUKCanadaAustraliaPakistanIrelandGermanyUSASwedenNew ZealandMalaysiaRussiaNetherlandDubaiSwitzerlandJapanVietnamItalyDenmarkOnlineGeorgiaLatviaSingaporeChinaNetherlandsIndiaFranceBelgiumBrazilColombiaEuropeEstoniaThailandNorwayNigeriaQatarCambodiaUAESouth KoreaAustriaTurkeyworldwideADB CountriesIndonesiaSaudi Arabia Industry Any Industry athletic apparel and footwear Refugee AgencyAccredited registrarAeronauticsAerospaceAirlineappliance manufacturerArtificial Intelligencearts, entertainment, and recreation sectorAstronomical ResearchAutomationAutomativeAviationBankingBioinformaticsBroadcastingBusiness Administrationcar manufacturingchemicalCivic and Social OrganizationsCivil EngineeringConsumer goodsCreativity and Innovation DevelopmentCyber SecurityDairyingData analyticsDevelopmentDigitale-commerceEducationEducationElectric Power GenerationEnergyEngineeringEngineering Professional…

Key Points Question  What is the association of PIK3CA mutations, response to therapy, and outcome by hormone receptor (HR) status and intrinsic subtype among patients with ERBB2/HER2-positive early breast cancer (EBC) treated in a clinical trial? Findings  In this cohort study of 184 patients enrolled in the phase 3 trial…

Job Description 6000! This is the number of associates in the Novartis Institutes for BioMedical Research (NIBR). This division is the innovation engine of Novartis, focusing on new technologies that have the potential to help produce therapeutic breakthroughs for patients. The Biologics Center (NBC) is accommodated within the Novartis Institutes…

Studies presented at the ASH Annual Meeting 2023 provided new insights and updates that may inform the treatment of lymphomas. Results from the phase 3 SYMPATICO trial showed that adding venetoclax to ibrutinib can improve progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL).1 These results…

Visiongain has published a new report entitled Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034: Forecasts by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), by Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology), by End-use (Pharma and Biopharma Companies, Research Institutes), by Disease (Oncology, Genetic Disorders,…

A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well the drug will match up against a radiopharmaceutical marketed by Novartis. The Point drug,…

The scenario for the biotech industry in 2024 looks upbeat after a challenging ride in 2023. New drug approvals, pipeline development, and an increase in mergers & acquisitions (M&A) activity boosted investor sentiment in the last couple of months, even though an uncertain macroeconomic environment was a headwind. Pharma and…

Tome Biosciences – a programmable genomic integration company – recently announced it has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence of any size into any programmed genomic location. And the company has raised…

(MENAFN– The Express Wire) The Global “CAR-T Cell Immunotherapies for Cancer Market ” Growth Forecast Report 20242031 is an essential tool for understanding the growth strategies, and various segments of industry by Type [ CD19, BCMA, EPCAM ] and Applications [ Hematological Cancer, Solid Tumor, Other Oncological Disorders ]. The…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Turns out Jay Bradner is moving from academia and Novartis to serve as Amgen’s new CSO. Also, the FDA has a new registry of trial sponsors and investigators…

Precision medicine is an approach to tailoring treatments based on people’s genetic makeup, lifestyles and environment. These targeted interventions can tackle diseases like cancer, neurological as well as metabolic diseases. The global market value of the precision medicine industry, encompassing many companies, crossed 70 billion last year, and is expected…

Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. Exton, PA, Dec. 13, 2023 (GLOBE NEWSWIRE) — Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS). These BTKis, administered orally, possess the…

PRESS RELEASE Published December 12, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes key companies continuously working towards developing Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Hodgkin Lymphoma Pipeline report…

Two gene therapies were approved for sickle cell disease last week, but for many researchers the Holy Grail remains something far more modest: A pill. Only the pharmacists’ oldest tool, they say, can actually have an impact on the scale of sickle cell. The gene therapies, with the risks and…

Introduction Reproxalap, a novel chemical entity in late-stage clinical development for the treatment of ocular inflammation, chemically sequesters a class of small molecules known as reactive aldehyde species (RASP). Via covalent binding to amine and thiol residues, RASP modulate the structure and function of proteins in an analog manner1 depending…

SAN DIEGO — In untreated chronic lymphocytic leukemia (CLL), patients who received ibrutinib plus venetoclax for a duration determined by disease characteristics rather than a fixed schedule had significantly better progression-free and overall survival compared with conventional chemoimmunotherapy, a new phase 3 analysis shows. The targeted therapy combination was also…

The field of RNA interference (RNAi) is witnessing significant growth with the approval of small interfering RNA (siRNA) drugs by the US FDA. These siRNA therapeutics offer a powerful and specific approach to target mRNA, with notable approvals like Patisiran, Givosiran, Lumasiran, Inclisiran, and Vutrisiran. The liver has been a…

What is Fibroblast Growth Factor Receptor 2 Inhibitor? Fibroblast Growth Factor Receptor 2 (FGFR2) inhibitors have emerged as a promising therapeutic class in the field of precision medicine, particularly in the treatment of certain types of cancer. These inhibitors selectively target the FGFR2 signaling pathway, which is responsible for stimulating…

The forecasted growth in the treatment of Diffuse Large B-cell Lymphoma (DLBCL) is driven by the increasing preference for targeted therapies. Targeted therapies, such as monoclonal antibodies and kinase inhibitors, offer a less toxic alternative to chemotherapy by focusing on specific molecular targets associated with cancer. Notable examples include rituximab…

Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform Technology, in-licensed from the Massachusetts Institute of Technology (MIT), capable of inserting DNA sequences of any size into any programmed genomic location Potential to create curative cell and integrative gene therapies Backed by leading biotech…

The pharmaceutical industry has reached a new milestone with the advent of a promising drug, Iptacopan (also known as Fabhalta), developed by Novartis. The company has recently reported positive topline results from a phase 3 trial of this drug, which is designed to treat a rare kidney disease known as…

First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal Phase 3 SEACRAFT-2 trial initiation in NRAS-mutated melanoma on track for H1 2024 SAN DIEGO,…

Pharmaceutical maker and biotechnology company Novartis is reporting positive topline results from a phase 3 trial of a drug to treat a rare kidney disease. Patients with the kidney disease, C3 glomerulopathy, who were taking 200 mg of iptacopan — also called Fabhalta — twice daily for six months were…

Novartis released promising data on Fabhalta (iptacopan), its recently approved drug for paroxysmal nocturnal hemoglobinuria, this time for a new indication — a rare disease called C3 glomerulopathy (C3G). Topline results from a Phase 3 study released Monday morning showed that iptacopan met its primary endpoint and was effective in…

The ongoing patent battle between COVID-19 vaccine giants, Pfizer-BioNTech and Moderna, has seen a new development when the European Patent Office (EPO) invalidated one of Moderna’s patents related to “respiratory virus vaccines.” BioNTech, in collaboration with Pfizer and Sanofi, opposed the patent, leading to its invalidation. The European patent process…

“It’s hoped that [longer persistence with oral DEC-C] would translate to better outcomes because those patients are able to stay on a treatment that takes time to work,” said Amer Zeidan, MD, in a presentation during the meeting. Retrospective, real-world results showed that oral decitabine and cedazuridine (DEC-C) and standard…

Results from the PARSIFAL-LONG study investigating endocrine-sensitive hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer demonstrated the efficacy of 2 combined option therapies, palbociclib (Ibrance; Pfizer) plus letrozole (Femara; Novartis) and palbociclib plus fulvestrant (Faslodex; Hikma), as first-line treatments for metastatic breast cancer. The study found no significant differences in progression-free survival…

Allied Market Research has published a study report Gene Therapy Market Size is Anticipated to Garner USD 46.5 billion by 2030, registering a CAGR of 22.8% Allied Market Research published a report, titled, “Gene Therapy Marketby Vector Type (Viral Vector, Non-Viral Vector), by Therapy (In Vivo Therapy, Ex Vivo Therapy), by…

Blau syndrome Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The report provides an overview including definitions, applications, product launches, developments, challenges, and regions. It is predicted that the market will show strong development due to the driven consumption in various…

Joyce O’Shaughnessy, MD The addition of pembrolizumab (Keytruda) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy improved pathologic complete responses (pCRs) in patients with early-stage, high-risk, estrogen receptor (ER)–positive/HER2-negative breast cancer, including subsets defined by geography, stage, baseline clinical lymph node involvement, and PD-L1 expression, according to data…

The US Food and Drug Administration (FDA) has approved iptacopan (Fabhalta, Novartis), the first oral monotherapy for both treatment-naive and pretreated adults with paroxysmal nocturnal hemoglobinuria (PNH).  Iptacopan, a factor B inhibitor, offers “superior hemoglobin improvement in the absence of transfusions” in patients with this rare chronic blood disorder, according…

The report furnishes a comprehensive analysis of the Global Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market for 2023, encompassing global, regional, and country-specific dimensions. It covers various aspects, including market sizes, segmentation market growth, competitive landscape, market share, sales analysis, and the influence of both domestic and global players in…

Merck KGaA’s highly anticipated experimental multiple sclerosis (MS) drug failed to meet its primary endpoint in two Phase 3 trials, the company announced this week. The EVOLUTION trials found that the drug, evobrutinib, didn’t meet its primary endpoint of reducing annualized relapse rates in patients with relapsing MS compared to…

Richmond, Dec. 06, 2023 (GLOBE NEWSWIRE) — According to a research report “Gene Therapy Market”, By Technology (Viral Vector-Based Gene Therapy {Adeno-Associated Virus (AAV), Lentivirus, Adenovirus, Retrovirus and Modified Herpes Simplex Virus}, Non-Viral Vectors-Based Gene Therapy {Electroporation, Gene Gun, Liposomes and Naked DNA}, CRISPR/Cas9 Technology), Therapy Type (Acute Lymphoblastic Leukemia…

PRESS RELEASE Published December 6, 2023 DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical and nonclinical stage products. It also covers the Osteoarthritis pipeline therapeutics assessment by…

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. Stanford is currently accepting patients for this trial. Eligibility Inclusion Criteria: Patients eligible for…

DelveInsight’s “Diffuse Large B-cell Lymphoma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. {Delhi, India} To strategically…

Chimeric antigen receptor (CAR) T-cell therapies have emerged as groundbreaking treatments for various hematologic cancers, demonstrating remarkable efficacy in targeting specific cancer cells. However, recent concerns raised by the U.S. Food and Drug Administration (FDA) have sparked an investigation into potential risks associated with these therapies. The FDA CAR T-cell…

Market Overview and Report Coverage Fibroblast Growth Factor Receptor 2 (FGFR2) is a protein found on the surface of cells that plays a crucial role in cell growth, division, and differentiation. It is a receptor for fibroblast growth factors (FGFs), which are a group of proteins responsible for controlling various…

Statsndata’s DNA Nanotechnology Market research reports provide all the information. It fuels market growth by providing customers with reliable data that helps them make critical decisions. Get a sample report:www.statsndata.org/download-sample.php?id=15160 Provides an overview including market, definition, applications and developments, and manufacturing technology. This DNA Nanotechnology market research report tracks all…

Tamin’ny Septambra 2020, i Kim dia voan’ny Lymphoma B-Cell Diffuse Large. Indrisy anefa fa tsy namaly ny fitsaboana tamin’ny voalohany i Kim. Ny ekipany ao amin’ny Hopitaly PA any Brisbane dia afaka nanondro azy ho any amin’ny ekipa mpitrandraka ao amin’ny RBWH mba hidirana amin’ny fitsaboana T-cell CAR vaovao. Hatramin’ny…

PRESS RELEASE Published November 29, 2023 The research study conducted by Coherent Market Insights on the “Car T Cell Therapy Market” spans over 100 pages and delves into various facets of this market. It analyzes the business strategies adopted by emerging industry players, examines the geographical scope, dissects market segments,…

Abstract A major unmet need in the cystic fibrosis (CF) therapeutic landscape is the lack of effective treatments for nonsense CFTR mutations, which affect approximately 10% of CF patients. Correction of nonsense CFTR mutations via genomic editing represents a promising therapeutic approach. In this study, we tested whether prime editing,…

Research Nester Key small interfering rna market players include GE HealthCare Technologies, Inc., Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis AG. New York , Nov. 29, 2023 (GLOBE NEWSWIRE) — The global small interfering rna (sirna) …

As per the report by Fortune Business Insights, The Biopharmaceuticals Market size is projected to reach USD 799.76 Billion by 2030, at a CAGR of 7.9% during the forecast period. Biopharmaceuticals Market Biopharmaceuticals Market (2023-2030) Pune, India, Nov. 27, 2023 (GLOBE NEWSWIRE) — The global biopharmaceuticals market size was USD…

GSK blood cancer drug Blenrep, withdrawn from the U.S. market just 12 months ago, may see renewed interest thanks to positive data from a combination trial. The Phase 3 study, dubbed DREAMM-7, showed that Blenrep, a BCMA-directed antibody drug conjugate (ADC), significantly extended the time to disease progression or death…

Data from several recent phase 3 trials support changes to standard care for non-small cell lung cancer (NSCLC), according to researchers. Results from the MARIPOSA trial suggest that amivantamab plus lazertinib represents a new first-line standard of care for patients with advanced, EGFR-mutant NSCLC.1 The MARIPOSA-2 trial suggests that amivantamab…

For Immediate Release Chicago, IL – November 24, 2023 – Today, Zacks Equity Research discusses Gilead Sciences, Inc. GILD, CRISPR Therapeutics AG CRSP, ACADIA Pharmaceuticals Inc. ACAD, Dynavax DVAX and Ligand Pharmaceuticals Inc. LGND. Industry: Biotech Link: www.zacks.com/commentary/2187656/5-biotech-stocks-likely-to-thrive-as-industry-prospects-look-bright It has been a choppy ride for the biotech industry in 2023…

Global Diffuse Large B-cell Lymphoma Therapeutics Market Forecast 2023-2032 The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032 The Business Research Company’s Diffuse Large B-cell Lymphoma Therapeutics Global Market Report 2023 identifies the increasing incidence…

The gene therapy market has evolved into a juggernaut in the healthcare sector, displaying an extraordinary trajectory of growth. As of 2023, the gene therapy market has surged to a remarkable value of USD 6.36 billion, and the projection for the forthcoming years is nothing short of astonishing. Forecasts indicate…

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

CRISPR therapies Pipeline (New York, USA) “CRISPR therapies Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CRISPR therapies Market. The CRISPR therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental…

In a landmark announcement for the CRISPR field and the sickle cell disease (SCD) community, the U.K. authorities have granted approval to Casgevy, the CRISPR-Cas9 therapy formerly known as exa-cel developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The U.S. Food and Drug Administration (FDA) is expected to follow suit in…

The global gene therapy market size reached US$ 5.1 Billion in 2023. By 2032, it will reach a value of US$ 16.8 Billion, growing at a CAGR of 13.9% (2024-2032). SHERIDAN, WYOMING, USA, November 16, 2023 /EINPresswire.com/ — How Big is the Gene Therapy Market? The global gene therapy market…

GEN Edge presents Gene Therapy Briefs, a roundup of commercial developments in gene therapy and other genome editing technologies. Gene Therapy Briefs has long appeared in the journal Human Gene Therapy, published by GEN publisher Mary Ann Liebert Inc., publishers. Elliott Investment Management, a fund manager with approximately $60 billion…

Remibrutinib, an investigational, highly selective Bruton tyrosine kinase (BTK) inhibitor, showed promising results in the treatment of chronic spontaneous urticaria (CSU) in the phase 3 REMIX-1 and REMIX-2 studies, according to a press release from Novartis. The findings were presented as a late-breaking abstract at the 2023 American College of Allergy,…

News Home Tuesday, November 14, 2023 10:04 AM | InvestorsObserver Analysts Mentioned in this article The market has been down on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bearish sentiment reading. Find out what this means…

According to HTF Market Intelligence, the Global Genetic Engineering market to witness a CAGR of 24.2% during the forecast period (2023-2029). The Latest Released Genetic Engineering Market Research assesses the future growth potential of the Genetic Engineering market and provides information and useful statistics on market structure and size. This…

In an early phase multicenter clinical study, large reductions in lipoprotein(a), or Lp(a), were achieved with a well-tolerated small interfering RNA (siRNA) therapeutic, lepodisiran. The reductions in serum Lp(a) in patients receiving lepodisiran were dose dependent but adverse events were not, said Steven E. Nissen, MD, professor of medicine at…

A single injection cut Lp(a) by 94% at 48 weeks and was well tolerated, findings that researchers say justify further studies. Lepodisiran, a long-duration, short-interfering RNA (siRNA), dramatically slashed Lp(a) levels in a small, phase I study presented this weekend at the American Heart Association (AHA) 2023 Scientific Sessions. Lead…

Review doi: 10.1016/j.blre.2023.101140. Online ahead of print. Affiliations Expand Affiliations 1 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States of America. 2 Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, United States of America; Case Comprehensive Cancer Center, Cleveland, OH,…

Competing interests JS reports a consulting role for AstraZeneca, Bayer, Kite and Sanofi, and institutional research funding from Ambrx, Arcus, Arvinas, BMS, Exelixis, Lilly, MacroGenics and Merck. SC reports consultancy to Astellas Pharma, Bayer, Beigene, Clovis, Janssen-Cilag, Johnson & Johnson, Novartis and Sanofi; research funding (self) from Clovis; and honoraria…

Abstract Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, open-label study…

Report Ocean has recently published a revised figures report on the worldwide CAR T Cell Therapy market. Growth prospects and difficulties are noted in the paper. A tool for evaluating the potential for new goods and services is the constraints and opportunity analysis. This aids businesses in locating and forecasting…

Key Points Question  Is clonal hematopoiesis of indeterminate potential (CHIP) detected at the time of hematopoietic stem transplant (HCT) associated with increased rates of cardiovascular disease (CVD) among patients with multiple myeloma (MM) following HCT? Finding  In this cohort study of patients with MM undergoing HCT, CHIP was highly prevalent…

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Increasing Funding, and Availability of Targeted Treatments. Cloves Syndrome Market Outlook Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevis, Spinal/Skeletal Anomalies/Scoliosis (CLOVES) syndrome is a very rare congenital (present at birth) disorder characterized by a combination…

November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights Epcoritamab (TEPKINLY®) was granted conditional marketing authorization by the European Commission (EC) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy Epcoritamab…

Only one biologic drug is approved for treating the hives and itchy rash caused by chronic spontaneous urticaria, an inflammatory skin disorder. Celldex Therapeutics’ lead program is shaping up as a viable and potentially superior alternative. The biotech reported preliminary Phase 2 data on Monday, showing its biologic, barzolvolimab, met…

[New York, November 2023] — An insightful market analysis report focusing on the Molecular Diagnostics Market has just been released by StatsNData, serving as a valuable resource for both industry leaders and newcomers. This comprehensive report offers a detailed exploration of the global Molecular Diagnostics market and its subsegments, providing…

BioTechX 2023, one of Europe’s largest conventions, that blends diagnostics, precision medicine and digital transformation in the field of healthcare, took place in the biotech hub of Basel, Switzerland. The event, which was held from October 4 to 6, hosted expert panelists who shared their knowledge on the digital transformation…

Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies. Dosed a total of 25 patients in Phase 1/2 STAAR study in Fabry disease, with promising clinical data continuing to emerge. Deferring additional…

Fibroblast Growth Factor Receptor 2 Inhibitor Market Analysis and Latest Trends Fibroblast Growth Factor Receptor 2 (FGFR2) Inhibitors are drugs that work by inhibiting the activity of the FGFR2 receptor, which plays a crucial role in cell growth, differentiation, and embryonic development. These inhibitors are primarily used in the treatment…

Company Logo Gene Therapy Market Gene Therapy Market Dublin, Oct. 31, 2023 (GLOBE NEWSWIRE) — The “Gene Therapy Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F” report has been added to ResearchAndMarkets.com‘s offering. The global Gene Therapy Market, valued at USD 6.01 billion in 2022, is set…

Abstract Low-level mosaic epimutations within the BRCA1 gene promoter occur in 5–8% of healthy individuals and are associated with a significantly elevated risk of breast and ovarian cancer. Similar events may also affect other tumor suppressor genes, potentially being a significant contributor to cancer burden. While this opens a new…

Novartis’s $3.2 billion acquisition of Chinook Therapeutics brought two drug prospects for a chronic kidney disorder with few approved treatments. One of these newly acquired drugs has now met the main goal of its Phase 3 test, results the Swiss pharmaceutical said will support plans to seek accelerated FDA approval…

The FDA has marked the 177Lu-PSMA-617 (Pluvicto) drug shortage status as resolved given unconstrained supply of the prostate cancer agent, announced Novartis, the developer of the therapy, in a news release.1 177Lu-PSMA-617 was approved in 2022 based on findings from the phase 3 VISION trial. According to the release, Novartis…

Shreeram Aradhye, MD Credit: Novartis Novartis has announced positive topline results from a 36-week interim analysis of the Phase 3 ALIGN study for atrasentan in patients with immunoglobulin A (IgA) nephropathy. Announced on October 30, 2023, the study met its primary efficacy endpoint of superiority compared to placebo for reduction…

By Giulia Petroni Novartis will submit an application next year for a possible accelerated approval of atrasentan in the U.S. after its phase 3 study met the primary endpoint. The Swiss pharmaceutical company said Monday that the study showed a significant reduction in proteinuria, a condition causing high levels of…

According to HTF Market Intelligence, the Global Nucleic Acid Testing market to witness a CAGR of 8.4% during forecast period of 2023-2028. The market is segmented by Nucleic Acid Testing Comprehensive Study by Type (Nucleic Acid Test Kits, Consumables), Nucleic Acid Test Kits (Ligase Chain Reaction (LCR), Transcription–mediated Amplification (TMA),…

Antitrust laws are put in place to prevent unlawful activities like price fixing, as well as monopolies from forming, typically tied to big pharma. If these powerful companies were to swallow smaller biotechs in an attempt to fix prices, it would stifle competition, result in limited options for consumers, thereby…

Lupus Therapeutics is partnering with AbbVie for the Phase 3 clinical program of upadacitinib for people with systemic lupus erythematosus (SLE). “The partnership with AbbVie will support the accelerated evaluation of upadacitinib as a potential treatment for individuals living with SLE,” Stacie Bell, PhD, Lupus Therapeutics’ executive vice president, said…

October 26, 2023 2 min read Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

DNA Repair Drugs Market Rise in incidence of cancer and advancements in DNA sequencing technologies WILMINGTON, DELAWARE, UNITED STATES, October 26, 2023 /EINPresswire.com/ — The global DNA repair drugs market offers a unique insight into key trends shaping the industry world-wide and in the largest markets. Written by some…

– Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months – – Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…

– Treatment with an RNAi Therapeutic Preserved Functional Capacity and Health Status and Quality of Life Compared with Placebo at 12 Months – – Patisiran Demonstrated an Encouraging Safety and Tolerability Profile in Patients with the Cardiomyopathy of ATTR Amyloidosis – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…

Data from the phase 3 clinical trial PSMAfore (NCT04689828) show lutetium (Pluvicto; Novartis) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) after treatment with androgen receptor pathway inhibitor (ARPI)…

Research by the Global Market Studies has reported a CAGR of 13.5% for the Global Epigenetics Market, expecting to surpass the USD 3 billion mark by 2028. LAS VEGAS, NEVADA, UNITED STATES, October 24, 2023 /EINPresswire.com/ — Research by the Global Market Studies has reported a CAGR of 13.5% for…

Dublin, Oct. 25, 2023 (GLOBE NEWSWIRE) — The “Molecular Diagnostics Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease Area, Technology, Product & Services, End User, and Geography” report has been added to ResearchAndMarkets.com‘s offering. The global molecular diagnostics market is…

Experimental design Primary T cell isolation, expansion, and cell culture Primary T cells were isolated from human peripheral blood mononuclear cells (PBMCs) of healthy donors collected by the Institute for Transfusion Medicine of the University Clinic of Leipzig, Germany, approved by the Ethics Committee of the Faculty of Medicine of…

The pioneering cartographer of the human genome, Craig Venter, discusses synthetic biology and his new book, “Sorcerer II: The Expedition That Unlocked The Secrets of The Ocean’s Biome” with Noema Editor-in-Chief Nathan Gardels. Nathan Gardels: Generative AI has been heralded lately as one of the great game-changing innovations of our…

A Crippling And Painful Disease Sickle Cell Disease (SCD) is a blood disease caused by a genetic mutation. This mutation creates abnormal hemoglobin, the protein carrying oxygen in the blood’s red cells. As a result, red cells are shaped like sickles and tend to get stuck in blood vessels, causing…

Ignace B. Vergote, MD, PhD In the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628), tisotumab vedotin-tftv (Tivdak) demonstrated a 30% reduction in the risk of death compared with investigator’s choice of chemotherapy when utilized in the second- or third-line for patients with recurrent or metastatic cervical cancer with disease progression on…

SoftMaskedAlphabet.CaseSensitiveTokenization (BioJava-1.7 API)  PREV CLASS   NEXT CLASS FRAMES    NO FRAMES     All Classes SUMMARY: NESTED | FIELD | CONSTR | METHOD DETAIL: FIELD | CONSTR | METHOD org.biojava.bio.symbol Class SoftMaskedAlphabet.CaseSensitiveTokenization java.lang.Object org.biojava.utils.Unchangeable org.biojava.bio.symbol.SoftMaskedAlphabet.CaseSensitiveTokenization All Implemented Interfaces: Annotatable, SymbolTokenization, Changeable Enclosing class: SoftMaskedAlphabet public class SoftMaskedAlphabet.CaseSensitiveTokenization extends Unchangeable implements SymbolTokenization This SymbolTokenizer works with a delegate to softmask symbol tokenization as…